QGEN dividend history

Highlights solutions addressing key oncology research needs across automated sample preparation, single-cell analysis, genomic profiling and data analysis QIAsymphony Connect will serve as a foundation for lab workflows, enabling standardized nucleic acid extraction for clinical and translational research Introduction of the QIAGEN Discovery Platform, an AI-grounding solution to power downstream AI applications and support drug discovery for research purposes QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrat

QIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making Launch marks QIAGEN's expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The lau

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-ri

FDA clears Gastrointestinal (GI) Panels for use on the fully automated QIAstat-Dx Rise platform, marking the ninth U.S. QIAstat-Dx panel clearance in last 24 months Laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system QIAstat-Dx Rise delivers higher-throughput automation for up to 160 tests per day with minimal hands-on time while supporting urgent sample prioritization QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndrom

QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN also to showcase new automation systems: QIAsymphony Connect for clinical applications and QIAmini for accessible low-throughput sample processing QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN's entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaini

Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a